Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) therapy(Utah State University)

N/A

Report date: 2024/02/06 20:00:33

Base Information

Drug NameAnti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) therapy(Utah State University)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacements
TargetsNot applicable
Therapy Area/IndicationsLymphoma, Large B-Cell, DiffusePrecursor Cell Lymphoblastic Leukemia-Lymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesUtah State University
China Registration ClassN/A

Develop Information

Active CompaniesUtah State University
Inactive CompaniesN/A
Active IndicationsLymphoma, Large B-Cell, DiffusePrecursor Cell Lymphoblastic Leukemia-Lymphoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A